CPMV — Mosaic Immunoengineering Share Price
0.000.00%
Last trade - 00:00- $4.13m
- $5.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing cancer therapies for areas of high unmet medical need. The Company has advanced an early-stage product candidate, MIE-101, that is based on a naturally occurring plant virus licensed from Case Western Reserve University (CWRU). Its product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (CPMV). The product is injected directly into a tumor and can act as an in-situ vaccine using markers of the injected tumor as the target which results in the activation of an immune response against the primary tumor and to prime systemic anti-tumor immunity, while reversing immunosuppressive signals in the tumor microenvironment (TME). In addition, the Company is pursuing new product candidates and platforms to expand its pipeline based on an understanding of immunotherapies and its license agreements with University of California San Diego.
Directors
- Carlton Johnson CHM (60)
- Steven King PRE
- Paul Lytle CFO
- Nicole Steinmetz CSO
- Robert Baffi DRC
- Robert Garnick DRC
- Gloria Felcyn IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 24th, 1992
- Public Since
- October 28th, 1993
- No. of Shareholders
- 645
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 7,242,137
- Address
- 9114 ADAMS AVE., #202, HUNTINGTON BEACH, 92646
- Web
- https://www.mosaicie.com/
- Phone
- +1 6572080890
- Auditors
- KMJ Corbin & Company LLP
Upcoming Events for CPMV
Q3 2024 Mosaic Immunoengineering Inc Earnings Release
Similar to CPMV
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Mosaic Immunoengineering share price?
As of Today at 22:10 UTC, shares in Mosaic Immunoengineering are trading at $0.55. This share price information is delayed by 15 minutes.
How has the Mosaic Immunoengineering share price performed this year?
Shares in Mosaic Immunoengineering last closed at $0.55 and the price had moved by -44.94% over the past 365 days. In terms of relative price strength the Mosaic Immunoengineering share price has underperformed the S&P500 Index by -53.79% over the past year.
What are the analyst and broker recommendations for Mosaic Immunoengineering?
There is no consensus recommendation for this security.
What is the Mosaic Immunoengineering dividend yield?
Mosaic Immunoengineering does not currently pay a dividend.
Does Mosaic Immunoengineering pay a dividend?
Mosaic Immunoengineering does not currently pay a dividend.
When does Mosaic Immunoengineering next pay dividends?
Mosaic Immunoengineering does not currently pay a dividend.
How do I buy Mosaic Immunoengineering shares?
To buy shares in Mosaic Immunoengineering you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mosaic Immunoengineering?
As of the previous close price of $0.55, shares in Mosaic Immunoengineering had a market capitalisation of $3.98m.
Where are Mosaic Immunoengineering shares listed?
Here are the trading details for Mosaic Immunoengineering:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CPMV
What kind of share is Mosaic Immunoengineering?
Based on an overall assessment of its quality, value and momentum Mosaic Immunoengineering is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mosaic Immunoengineering share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Mosaic Immunoengineering share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mosaic Immunoengineering. Over the past six months, its share price has underperformed the S&P500 Index by -2.53%.
As of the last closing price of $0.55, shares in Mosaic Immunoengineering were trading -28.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mosaic Immunoengineering PE Ratio?
The Mosaic Immunoengineering PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mosaic Immunoengineering?
Mosaic Immunoengineering's management team is headed by:
- Carlton Johnson - CHM
- Steven King - PRE
- Paul Lytle - CFO
- Nicole Steinmetz - CSO
- Robert Baffi - DRC
- Robert Garnick - DRC
- Gloria Felcyn - IND